X-linked mental retardation is a very common condition that affects approximately 1 in 600 males. Despite recent progress, in most cases the molecular defects underlying this disorder remain unknown. Recently, a study using the candidate gene approach demonstrated the presence of mutations in PAK3 (p21-activating kinase) associated with nonspecific mental retardation. PAK3 is a member of the larger family of PAK genes. PAK proteins have been implicated as critical downstream effectors that link Rho-GTPases to the actin cytoskeleton and to MAP kinase cascades, including the c-Jun amino-terminal kinase (JNK) and p38. We screened 12 MRX pedigrees that map to a large region overlying Xq21-q24. Mutation screening of the whole coding region of the PAK3 gene was performed by using a combination of denaturing gradient gel electrophoresis and direct sequencing. We have identified a novel missense mutation in exon 2 of PAK3 gene (R67C) 
INTRODUCTION
X-linked mental retardation (XLMR) is a very common condition that affects about 1 in 600 males. It can be syndromal or nonspecific (MRX). Until recently, FMR2 was the only gene known to be involved in MRX [Gecz et al., 1996; Gu et al., 1996] . Over the past 2 years, despite the complexity of the extensive genetic heterogeneity, positional cloning efforts based on either the investigation of balanced X;autosome translocations, deletion mapping, or candidate gene strategy allowed to identify, so far, four different genes involved in MRX [Chelly, 1999] . The first one, called oligophrenin 1, encodes a rhoGTPase-activating protein [Billuart et al., 1998 ]. The second gene is GDI1, a rab-GDP-dissociation inhibitor, implicated in synaptic vesicle cycling and neurotransmitters release [D'Adamo et al., 1998 ]. The third gene, PAK3, is a member of the larger family of p21-activating kinase (PAK) [Allen et al., 1998 ], and the fourth gene, IL1RAPL (interleukin-1 (IL-1) receptor accessory protein like) encodes a 696-amino acids protein that has significant homology to IL-1 receptor accessory proteins [Carrié et al., 1999] .
PAK3, implicated in family MRX30 [Allen et al., 1998 ], is a member of the family of PAK genes that also includes human PAK1, PAK2, and PAK4 [Sells and Chernof, 1997; Abo et al., 1998 ]. PAK proteins are highly conserved in their amino-acid sequence and have been implicated as critical downstream effectors that link Rho-GTPases to the actin cytoskeleton and to MAP kinase cascades, including the c-Jun aminoterminal kinase (JNK) and p38. In the MRX30, the mutation R419X produces premature termination, leading most likely to a loss of function of PAK3.
In order to evaluate the frequency of PAK3 mutations among mapped familial cases of MRX, we screened for point mutations mentally retarded individuals from 12 different MRX pedigrees, including a large French family (MRX47), which are linked to the Xq21-q24 region [des Portes et al., 1997] . Screening of the whole coding region of the PAK3 gene was carried out by using a combination of denaturing gradient gel electrophoresis (DGGE) and direct sequencing analyses. We identified a novel missense mutation R67C in the propositus of the MRX47 family.
MATERIALS AND METHODS Patients
We analysed 12 extended families with idiopathic mental retardation (10 nonspecific and two syndromal). Linkage analyses had previously shown the most likely location of the disease in Xq21-q24 region in each family either by exclusion mapping (lod score <2) or by linkage analysis (lod score >2) ( Table I ). Fragile X syndrome was excluded by Southern-blot analysis using DNA digested with EcoRI/EagI endonucleases and StB12-3 probe corresponding to the FRAXA locus [Rousseau et al., 1991] . Ethics committee approval and patient or family consent was obtained.
Mutation Analysis

DGGE.
DNA was extracted from peripheral-blood leukocytes or lymphoblastoid cells, and the 14 exons and the flanking intronic sequences of the PAK3 gene were separately polymerase chain reaction (PCR)-amplified from genomic DNA using primers, listed in Table II , with psoralen clamps. DGGE conditions were chosen according to the Meltmap program, kindly provided by L. Lerman and colleagues. The denaturants were 7 M and 40% formamide, and gels run at 60°C [Myers et al., 1987; Bienvenu et al., 1995] . PCR products were subjected to electrophoresis as described in Table III .
Mutation identification. PCR products showing an abnormal migration pattern on DGGE analysis were directly sequenced on an automated sequencer (ABI 377, Perkin-Elmer Applied Biosystems, Foster City, CA) using the dye-terminator method. Usually sequence variations are checked by restriction analysis of genomic DNA. Exon 4 of the PAK3 was analysed by direct sequencing of PCR products (4F 5Ј gaatgaaacattctttatga 3Ј and 4R 5Ј aacagttttcaatttttcac 3Ј).
RESULTS
Summary of genetic data in the 12 families with mental retardation mapped to the Xq21-q24 region are shown in Table I [The European XLMR Consortium, 1999] . Coding exons of the PAK3 gene were screened for mutations by DGGE in 12 affected males. No abnormalities were detected in all exons except exon 2. The screening showed the presence in one patient with MRX of an abnormal migration pattern of exon 2. The sequence of the PCR product of exon 2 showed a C to T substitution at cDNA position 199 ( Fig. 1 ). This change causes arginine (CGC) to cysteine (TGC) substitution at amino acid 67 of the PAK3 protein. As the missense mutation destroys a unique restriction HhaI site, this event was used to study the segregation of this base substitution in the entire family of this patient. Figure  2 shows co-segregation between the mutation and the mental retardation phenotype. This base substitution was absent in 110 normal controls.
This missense mutation is located in a polybasic region upstream of the Cdc42/Rac interactive binding (CRIB) domain. It has been shown that mutations of the basic residues to neutral residues reduce RhoGTPases binding to Pak and reduce or abolish Pak activation by Rho-GTPases [Knaus et al., 1998 ].
In this MRX47 family, all affected males (III-5, III-8, III-12, IV-2, IV-3, IV-7) show moderate to severe mental retardation. Clinical and neuropsychological data of the affected males were previously reported [des Portes et al., 1997] . No seizures, statural growth deficiency, neurological impairment, or minor facial or other physical anomalies were observed.
DISCUSSION
In order to evaluate the frequency of PAK3 mutations among mapped familial cases of MRX, we have carried out a systematic analysis of the PAK3 gene in 12 patients with MRX, and we have screened, using DGGE, the whole coding region of this gene. Upon analysis of exons 1 through 14, we have identified a novel missense mutation that predicts a change of an arginine to cysteine (R67C) that represents a nonconservative amino acid substitution. This novel missense mutation is likely to be pathogenic because: 1) it cosegregates with the disease trait in the large family MRX47 previously localized in Xq23.3-q24 with a 2-point lod score >3 [des Portes et al., 1997] ; 2) it changes a conserved residue during evolution (Fig. 3) ; and 3) it was not found in 110 control chromosomes. The p21-activated kinases (PAKs) are evolutionarily conserved regulators of the actin cytoskeleton organization [Sells and Chernof, 1997] . The yeast Pak Ste20 regulates polarized cell growth in response to mating pheromone, and mammalian Paks reorganize the actin cytoskeleton when over-expressed in tissue-culture cells. Pak is a protein that regulates its proper activity through interaction between the N-terminal regulatory region and the C-terminal kinase domain. The regulatory region contains binding sites for at least three types of signaling proteins. An N-terminal proline-rich sequence (PXXP) binds to Nck; a CRIB motif binds to GTP-bound forms of Cdc42 and Rac; and a proline-rich motif is constitutively bound to Pix, a guanine nucleotide exchange factor specific to Rac and Cdc42 [Obermeier et al., 1998 ]. In the inactive state, an autoinhibitory sequence adjacent to the CRIB motif inhibits Pak kinase activity.
The novel missense mutation is located in a polybasic region upstream of the CRIB domain. PAK1, 2, and 3 have 100% sequence identity in both the CRIB domain and the polybasic domain (AA 66-68 in human PAK1). It has been shown that mutation of the basic Lys residues of Pak1 to neutral Gln residues (K66-68Q and K66-68L) reduces Rac1 and Rac2 binding to Pak1 and reduces or completely abolished Pak1 activation by Rac1, Rac2, or Cdc42. These results suggest that the polybasic region (66-68) plays an important role in Pak activation by Rac1, Rac2, and Cdc42 proteins [Knaus et al., 1998 ]. Our novel missense mutation R67C alters the basis charge of the region and should alter the GTPase binding and stimulation of Pak activity. This result confirms that the positively charged domain is likely to be important for the biological activity of the PAK isoforms.
This finding, together with previous reports [Billuart et al., 1998; D'Adamo et al., 1998; Chelly, 1999] raises the issue of the cellular bases underlying mental retardation resulting from dysfunction of pathways regulated by Rho-GTPases proteins. The Rho-GTPases, in particular RhoA, Rac1, and Cdc42 act as molecular switches, which integrate various intracellular signaling pathways to mediate a coordinated behaviour of the actin cytoskeleton. The cellular functions of the Rho proteins have mainly been studied in fibroblasts, where RhoA directs the formation of stress fibers, Rac1 is involved in lamellipodia formation, and Cdc42 stimulates formation of filopodia. For example, Rho is an inhibitor of neurite outgrowth, whereas Cdc42 acts upstream of Rac1 and promotes neurite outgrowth by regulating the formation of growth cone filopodia and lamellae [Kozma et al., 1997] . Thus, neurite outgrowth appear to be guided through the combined operation of different guidance mechanisms (short-and long-range attraction, and short-and long-range repulsion), and the outcome of any particular guidance decision appears to reflect the balance of attraction and repulsion operating at the decision point. Abnormalities in the coordinated effects of these Rho proteins on the organization of the actin cytoskeleton could result in alteration of growth cone morphology and network formation of neurons. Thus, mutations in a gene like PAK3 could modify binding of activated Cdc42/rac to Pak, change the dynamics of the actin cytoskeleton, and/or Fig. 3 . Multiple alignment of a part of the N-terminal domain of Pak proteins. The site of mutation is shown in bold; the CRIB motif is underlined; # corresponds to the binding-inactivating mutations K66-68L, K66-68R, and K66-68Q of PAK-1 [Knaus et al., 1998 ]; * corresponds to residues conserved in all proteins. affect neurite outgrowth, neuronal morphogenesis, or establishment of neuronal connections. Disruption of these processes could be a cellular basis for mental retardation. In summary, our data further confirm that mutations in the PAK3 gene are associated with MRX. Other proteins involved in this pathway (i.e., Nck (an SH3/SH2 adaptor protein) and Pix) are probably potential candidate genes for mental retardation.
However, as for the previously described genes, such as OPHN1, GDI1, IL1RAPL [Billuart et al., 1998; D'Adamo et al., 1998; Allen et al,. 1998; Carrié et al., 1999] , mutations in PAK3 seem to be very rare, and the absence of mutations in most families mapped in genetic intervals that encompass the position of each gene is most surprising. These data suggest the presence of at least one additional gene in each genetic interval, making the number of genes involved in mental retardation at least double that previously estimated number.
